Sex-dependent differences in cardiovascular disease (CVD) susceptibility and progression may be estrogen-mediated, but the genetic pathways regulating estrogen cardioprotection have yet to be elucidated. Receptor Activity Modifying Proteins, or RAMPs, are transmembrane accessory proteins that are known to interact with G-protein coupled receptors (GPCRs) and play a role in receptor trafficking and ligand specificity. RAMP3 is unique in that it is transcriptionally induced by estrogen and CVD. Also, unlike other RAMP family members, RAMP3 is known for its ability to alter GPCR recycling to the plasma membrane through a PDZ motif-dependent association with NSF. GPER1 is a novel cardioprotective estrogen-binding GPCR that is present in increased levels in females and in CVD. Our preliminary findings have shown that genetic loss of RAMP3 leads to reduced levels of GPER1 at the plasma membrane of cardiac cells in a sex-dependent fashion, providing evidence for an interaction of RAMP3 with GPER1. We will investigate the potential interaction between RAMP3 and GPER1 in vitro using transfected cells to determine whether RAMP3 can alter GPER1 recycling to the plasma membrane. In addition we will perform in vivo studies to determine whether pharmacological activation of GPER1 signaling affects the cardiovascular phenotype of RAMP3-/- male and female mice on a genetic background of heart failure. Results from this proposal will elucidate the role of RAMP3 and GPER1 in sex-dependent cardioprotection and have the potential of identifying novel therapeutic targets for gender-tailored treatment of CVD.
Narrative Heart Disease is a common health condition that ranks as the leading cause of death for both men and women in the United States, causing over 630,000 deaths each year. This means that one out of every four deaths in the U.S. is due to heart disease. Though heart disease affects both men and women, for reasons we do not fully understand, it affects the two sexes differently. Prior to menopause, women are generally protected from heart disease while men of the same age are at increased risk in comparison. However, after menopause, a woman's risk of developing heart disease drastically increases. Sex-dependent differences in heart disease susceptibility and progression may be mediated by estrogen, but the genetic pathways that regulate this effect have not yet been clearly identified. In this research proposal we will investigate specific signaling pathways that may be involved in the sex-dependent differences of heart disease. Because heart disease is such a prevalent and serious threat to American health, these studies are important to clarify the mechanisms that underlie the development and progression of this condition, with the overall goal of improving human health.
|Lenhart, Patricia M; Nguyen, Thutrang; Wise, Alison et al. (2014) Adrenomedullin signaling pathway polymorphisms and adverse pregnancy outcomes. Am J Perinatol 31:327-34|
|Lenhart, Patricia M; Broselid, Stefan; Barrick, Cordelia J et al. (2013) G-protein-coupled receptor 30 interacts with receptor activity-modifying protein 3 and confers sex-dependent cardioprotection. J Mol Endocrinol 51:191-202|
|Lenhart, Patricia M; Caron, Kathleen M (2012) Adrenomedullin and pregnancy: perspectives from animal models to humans. Trends Endocrinol Metab 23:524-32|
|Barrick, Cordelia J; Lenhart, Patricia M; Dackor, Ryan T et al. (2012) Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner. J Mol Cell Cardiol 52:165-74|